Clinical trial
Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients…
NCT00476268 · Chiesi Farmaceutici S.p.A., Industry · Completed
Key facts
| NCT number | NCT00476268 |
|---|---|
| Title | Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma |
| Official title | A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma |
| Lead sponsor | Chiesi Farmaceutici S.p.A., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | beclomethasone/formoterol (100/6µg) pMDI, Beclometasone dipropionate 250 µg/unit dose pMDI, Formoterol powder 12 µg/unit dose |
| Enrollment | 824 |
| Start date | Feb 1, 2004 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | May 21, 2007 |
| Last update posted | Oct 31, 2024 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: